Trials / Completed
CompletedNCT02126306
Beta Glucosylceramide for Treatment of NASH
Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.
Detailed description
Patients with NASH to receive the treatment versus placebo for 40 weeks followed by a liver biopsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Beta Glucosylceramide | Beta Glucosylceramide |
| DRUG | Placebo | normal saline |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2014-04-30
- Last updated
- 2014-10-30
- Results posted
- 2014-08-18
Source: ClinicalTrials.gov record NCT02126306. Inclusion in this directory is not an endorsement.